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RESEARCH
Perspectives on extended-release naltrexone 
induction among patients living with HIV 
and opioid use disorder: a qualitative analysis
Kim A. Hoffman1* , Robin Baker1, Laura C. Fanucchi2, Paula J. Lum3, Lynn E. Kunkel4, Javier Ponce Terashima5, 
Dennis McCarty3, Petra Jacobs6 and P. Todd Korthuis1,4 
Abstract 
Background: The CHOICES study randomized participants with HIV and opioid use disorder (OUD) to HIV clinic-
based extended-release naltrexone (XR-NTX), which requires complete cessation of opioid use, versus treatment-as-
usual (i.e., buprenorphine, methadone). Study participants randomized to XR-NTX were interviewed to assess their 
experiences with successful and unsuccessful XR-NTX induction.
Methods: Semi-structured qualitative interviews were completed with a convenience sample of study partici-
pants with HIV and OUD (n = 37) randomized to XR-NTX in five HIV clinics between 2018 and 2019. All participants 
approached agreed to be interviewed. Interviews were digitally recorded, professionally transcribed, and analyzed 
using thematic analysis.
Results: Participants included women (43%), African Americans (62%) and Hispanics (16%), between 27 to 69 years 
of age. Individuals who completed XR-NTX induction (n = 20) reported experiencing (1) readiness for change, (2) a 
supportive environment during withdrawal including comfort medications, and (3) caring interactions with staff. Four 
contrasting themes emerged among participants (n = 17) who did not complete induction: (1) concern and anxi-
ety about withdrawal including past negative experiences, (2) ambivalence about or reluctance to stop opioids, (3) 
concerns about XR-NTX effects, and (4) preferences for other medications.
Conclusions: The results highlight opportunities to improve initiation of XR-NTX in high-need groups. Addressing 
expectations regarding induction may enhance XR-NTX initiation rates.
Trial Registration ClinicalTrials.gov: NCT03275350. Registered September 7, 2017. https:// clini caltr ials. gov/ ct2/ show/ 
NCT03 275350? term= exten ded+ relea se+ naltr exone & cond= Opioid+ Use.
Keywords: Extended-release naltrexone, Opioid withdrawal, Induction, Opioid use disorder, HIV
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Background
Approximately 2 million individuals in the U.S. have an 
opioid use disorder (OUD) [1] and only a fraction receive 
medications for opioid use disorder (MOUD) treatment 
[2, 3]. Untreated OUD is associated with increased HIV 
risk behaviors [4, 5], decreased receipt of antiretroviral 
therapy (ART) [5–7], decreased ART adherence [5, 8–
10], and decreased HIV viral suppression [11, 12]. Treat-
ment of OUD can increase engagement in HIV care and 
enhance health outcomes [11, 13]. MOUD with an opioid 
receptor agonist (methadone), partial agonist (buprenor-
phine), or opioid antagonist (extended-release naltrex-
one) effects at the opioid mu receptor facilitate recovery 
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from OUDs [14]. Only 36% of specialty substance use 
disorder treatment organizations in the U.S., however, 
provide MOUD [15].
Despite compelling evidence that MOUD is effective 
[15–19], these medications remain underutilized [20]. 
This is due in part to the need for daily dosing. Recent 
advances are changing the landscape; some partial and 
full antagonist treatments such as extended-release for-
mulations of naltrexone (XR-NTX) and buprenorphine 
provide alternatives to the daily dosing requirements of 
methadone. XR-NTX, a deep muscle injection that lasts 
28 days, eliminates the need for daily dosing. While long-
acting formulations may improve treatment adherence, 
a recent study found that it was more difficult to initi-
ate XR-NTX than buprenorphine in patients with OUD 
[19]; the process of initiating XR-NTX so that someone 
receives their first injection (a.k.a. “induction”) requires 
an opioid-free state several days prior to initiation, and 
opioid withdrawal can be difficult to complete even in 
inpatient settings with supportive medication [21]. In 
contrast, buprenorphine induction does not require com-
plete abstinence from opioids; first dose of buprenor-
phine may be administered 12–24  h after last use of 
opioids. Multi-site trials in North America and Europe 
noted that some individuals randomized to XR-NTX did 
not complete induction; induction rates were enhanced 
in inpatient settings (75%–90%) compared to primarily 
outpatient settings (68%) [19, 22–24].
A 51-patient pilot study demonstrated the feasibility of 
XR-NTX for the treatment of opioid and alcohol use dis-
orders in two HIV primary care clinics [22]. Mean days 
of opioid use in the past 30  days decreased in both the 
treatment as usual group (i.e., methadone or buprenor-
phine) (17.3 to 4.1  days) and the XR-NTX group (20.3 
to 7.7 days). HIV suppression increased from 67 to 80% 
for XR-NTX and 58% to 75% for treatment as usual [22]. 
However, only 42% of participants with OUD assigned 
to XR-NTX completed induction [22]. Based on these 
pilot data, the “Comparing Treatments for HIV-Infected 
Opioid Users in an Integrated Care Effectiveness Study 
(CHOICES) Scale-up study” (CTN-0067) was redesigned 
and expanded to five HIV clinics willing to randomize 
patients to either opioid agonist therapy or opioid antag-
onist therapy. Of 55 participants randomized to XR-
NTX, 26 completed an XR-NTX induction.
Methods
We contacted 37 of the 55 participants randomized to 
XR-NTX to conduct semi-structured, in-depth inter-
views (20 induced, 17 not induced) from five participat-
ing HIV clinics between 2018 and 2019, during early 
study implementation. Study participants were selected 
because they completed or did not complete a first 
XR-NTX injection, and the interview guides and analysis 
were designed to assess how the experiences differed. The 
semi-structured research guides were created by the core 
qualitative research team. We used a convenience sam-
pling approach (based on participant and clinic schedul-
ing availability) and all participants approached for the 
interview agreed to participate. Qualitative interviews 
assessed the opioid withdrawal and XR-NTX induction 
experience for participants randomized to XR-NTX to 
identify more effective strategies for initiating opioid 
antagonist therapy. For those who did not initiate XR-
NTX, study participants were interviewed about their 
induction attempt experience. Interviews were digitally 
recorded, professionally transcribed, and examined using 
thematic analysis [25].
Participant eligibility
Individuals with moderate or severe OUD and an HIV 
viral RNA level of ≥ 200 copies/ml were eligible for the 
CHOICES Scale Up Study. Participants randomized to 
XR-NTX were eligible for qualitative interviews and 
recruited during their scheduled clinic appointments 
for MOUD, HIV care, or study visits. Potential interview 
participants were informed of the overall aims of the 
qualitative study and invited to participate in either face-
to-face or telephone interviews. All individuals invited to 
complete interviews agreed to participate. Participants 
received a $50 gift card for their participation. The study’s 
Central IRB reviewed the interview guides and approved 
an information sheet for study participants [26].
Interviews
The semi-structured research guide was created by 
the core qualitative research team; core research ques-
tions were asked but the interview allowed for follow-
up probes by the investigator based on answers to the 
original question. Two highly experienced qualitative 
interviewers (KH and RB), who were not responsible for 
enrolling participants in the clinical trial, conducted the 
interviews. Face-to-face interviews (n = 19) were con-
ducted in a private clinic room with only the interviewer 
and the participant present. In the case of telephone 
interviews (n = 18), study staff facilitated the initiation 
of the call and then left the room so that the conversa-
tion between the interviewer and respondent was pri-
vate. Interviews lasted between 20 and 40 min, averaged 
33  min, and were digitally recorded. Interview topics 
included: (1) participant characteristics, (2) current and 
prior HIV care, (3) history of alcohol and drug use, (4) 
substance use treatment history, (5) social supports, and 
(6) views on medications for OUD including withdrawal 
and induction experiences. Interviews were completed, 
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recorded and professionally transcribed between July 
2018 and November 2019.
Analysis
Given the research aim to elicit how respondents con-
structed their own lived experience, a Constructivist 
paradigm [27] was used. Within that paradigm, the team 
followed Braun and Clarke’s [25] Thematic Analysis (TA) 
as a specific approach to analysis. When applying TA, the 
six-step procedures defined by Braun and Clarke were 
applied. Themes were identified which related to opi-
oid withdrawal and XR-NTX induction experiences and 
barriers to induction using an inductive approach at the 
semantic level. Three PhD level investigators (KH, RB, 
DM) with extensive experience in qualitative data collec-
tion, analysis and publication [21, 28–31] drafted a list of 
preliminary themes after reading interview transcripts 
and two coded transcript themes (KH, RB). An inter-
coder reliability process assessed coding discrepancies 
and a third coder (DM) adjudicated the coding [32]. Ten 
percent of the transcripts were double-coded to achieve 
an inter-coder reliability rate of 85%. After achieving 
agreement on the themes, representative quotations were 
selected by consensus. Atlas.ti 8 software facilitated data 
processing and quotation retrieval.
Results
Participants included women (43%), African Ameri-
cans (62%) and Hispanics (16%), between 27 to 69 years 
of age (see Table 1). Twenty participants who had com-
pleted XR-NTX induction reported (1) readiness for 
change, (2) a supportive environment during withdrawal 
including comfort medications, and (3) caring interac-
tions with staff. Four contrasting themes emerged among 
participants (n = 17) who did not complete induction: 
(1) concern and anxiety about withdrawal including past 
negative experiences, (2) ambivalence about stopping 
opioids, (3) concerns about XR-NTX effects, and (4) 
preferences for other medications.
Themes associated with successful XR‑NTX induction
Readiness for change
For respondents who successfully completed induction, 
the most common theme which emerged was around 
their readiness to undergo induction. Before persons 
with OUD begin treatment with XR-NTX, they must 
be opioid-free prior to the first injection. If opioids are 
present, the XR-NTX will displace the opioids from 
their receptors and produce symptoms of opioid with-
drawal, a constellation of uncomfortable, often severe, 
flu-like symptoms. All CHOICES study participants 
reported common opioid withdrawal symptoms such as 
pain, diarrhea, nausea, headaches, and backaches. Given 
the discomfort of opioid withdrawal, participants were 
asked to talk about their motivation for induction onto 
XR-NTX. Participants spoke of their families, a desire to 
improve their lives, and being tired of life on opioids:
I think the will. Yes. Yes. … My wife, my children. I 
have grown-up kids and I don’t want them to con-
tinue seeing me like this. … My wife has always 
stayed with me… She has always been there with 
me.[Case ID 32]
I just told myself ‘I wanted a better life’. [Case ID 19]
I’m really actually– I’m tired of getting– I’m tired… I 
tell you I am tired. [Case ID 27]
Another related how their experience with overdose 
and fear of dying provided motivation for induction onto 
XR-NTX:
I OD’ed. Yeah. And I never overdosed on any sub-
stance before and every day I had to build up my 
Table 1 Participant characteristics
N = 37
Age n %
Mean Age 51 years old
 27–39 7 19
 40–59 23 62
 60–69 7 19
Gender
 Men 21 57
 Women 16 43
Race
 White 8 22
 African American or Black 23 62
 Hispanic 6 16
Education
 Less than High School graduate 18 48
 High School graduate or GED 8 22
 Some college 8 22
 Associates degree 1 3
 Bachelor’s degree 2 5
Marital status
 Married/life partner 2 5
 Divorced 8 22
 Never married 21 57
 Separated 4 11
 Widowed 2 5
Employment status
 Employed 4 11
 Unemployed or looking for work 19 51
 Disabled 10 27
 Retired 4 11
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mind, my body and my spirit to not use. It was a 
hard thing to do. It was a struggle; my body is crav-
ing something and me saying no because I could die. 
It was very hard but I did it. [Case ID 24]
One respondent recognized that study incentives 
helped him complete the painful process of withdrawal 
and gave him a sense that participation in the study was 
beneficial.
The study was a way to get extra money and based 
on the information they gave me about the risk and 
what they were trying to accomplish I felt like I could 
do it and … it was a worthwhile endeavor for me. 
[Case ID 25]
Similar themes related to motivation to change were 
echoed in advice that participants had for others who 
were considering XR-NTX. Participants stressed the 
importance of readiness and individual commitment to 
stop opioid use and the importance of wanting to stop 
opioid use.
Just make sure that you really want to stop using 
because it do work. You have to be ready to stop 
using and so be ready. Some be ready and they be 
scared but it works. They don’t need to be scared but 
just give yourself a chance. [Case ID 18]
I think other people who want to get clean, it’s going 
to work perfectly. For other people who are doing it 
for the wrong reasons, I think it’s going to keep them 
from getting high but it’s not going to stop them from 
wanting to use. The will has to be there. The body 
will follow. [Case ID 30]
A supportive environment during withdrawal 
including comfort medications
Another commonly discussed theme included discus-
sion about the environment in which the respondents 
underwent withdrawal. Participants completed opioid 
withdrawal in inpatient facilities for medically managed 
withdrawal, jails, at home, and on the streets with vary-
ing levels of comfort and success. Many participants had 
difficulty accessing inpatient medically supervised with-
drawal due to long waiting lists. While some participants 
withdrew from opioids successfully at home, others 
reported that home was a suboptimal location due to 
ongoing availability of opioids or concerns about safety.
[If I tried to] withdraw at home, I would end up 
using. I made up my mind to go on the treatment 
because I really wanted the injection [XR-NTX]. 
[Case ID 33]
Prior to getting the shot [XR-NTX], I tried to detox 
because I didn’t want to go into [inpatient] detox. 
I lasted about maybe a week or two, and that was 
on the streets. That was hell, because everywhere 
around me, everyone was using. [Case ID 30]
A respondent who completed withdrawal at home 
mentioned that their friends in recovery checked on 
them regularly throughout the process. They observed 
that they would have been more comfortable in an inpa-
tient facility if that had been an option. Although their 
brothers and sisters checked on them regularly, for exam-
ple, this participant would have preferred admission to 
an inpatient facility for withdrawal management.
You need to be like somewhere where they can moni-
tor your vitals. You can’t do it by yourself. I had my 
apartment. They were there with me for the seventy-
two hours but you need someone in case your body 
just stops and you can’t do it alone. All my brothers 
and sisters are in recovery now and they were calling 
and coming back. [Case ID 24]
Participants who used medically managed withdrawal 
facilities attributed their success to access to ancillary 
medications and a supportive environment.
You know, you can relax and rest. You get the rest 
you need and just focus on you. And then you have 
medical assistance with problems or struggles or 
anything like that or if you feel like crap you don’t 
go, you know, and look to use. You just, you know, 
get the help that you need to get through the medical 
stuff. [Case ID 20]
Caring interactions with others
Though less commonly cited, a final theme among the 
inducted participants was the critical role of supportive 
study staff in helping them complete opioid withdrawal 
and XR-NTX induction. Participants commented that 
study staff provided both educational, operational, and 
emotional support. These supports included information, 
flexibility to accommodate life responsibilities such as 
child care, and medications that helped to alleviate with-
drawal symptoms.
Well, yes, yes, they did treat me well here, truly, they 
treated me like I was family. I would come here with 
my daughter because my wife couldn’t look after 
her. So, sometimes, I had to take care of my daugh-
ter. Here, they took care of her while I was being seen 
and all, they have treated me very well here. [Case 
ID 32]
They did everything–awesome. Very awesome and 
very, you know, good at explaining everything and 
good at getting through all the paperwork. [Case ID 
26]
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My doctor—my psychiatrist gave me the pills for 
when I get sick, like stomach cramps, runny nose, 
something for my, you know, the bones when I be 
aching and stuff like that, she gave me medication 
for all that. [Case ID 02]
Emotional support included compassion, encour-
agement, and helping participants cope with fears and 
anxieties.
I don’t like needles at all so I had to mentally get 
ready for that. So when Dr. (name) was there to do 
the shot, okay, the lady (nurse) was like I am going 
to hold your hand like this. Okay, ready. Go. And 
he just like, was already done. Already put it in and 
took it out and I’m still holding her hand waiting. I 
didn’t even feel anything.” [Case ID 26]
My caseworker and [study staff helped] because they 
talked with me and I wanted to prove to them that I 
could do right. They let me know that there is some-
body in this world that wants to see you get right. 
And this … made me realize that some people in this 
world will help you. [Case ID 19]
Themes associated with unsuccessful XR‑NTX induction
Study participants who were unable to complete induc-
tion emphasized fear of withdrawal, ambivalence about 
stopping drug use, misperceptions of XR-NTX and a 
preference for opioid agonist therapy.
Concern and anxiety about withdrawal 
including past negative experiences
The most commonly discussed theme which emerged 
concerned worry about withdrawal. Among individu-
als randomized to XR-NTX, fear of completing opioid 
withdrawal was a common barrier to induction. They 
described the physical and emotional symptoms associ-
ated with previous opioid withdrawal, including gen-
eralized pain, nausea, vomiting, diaphoresis and severe 
anxiety. A 27-year-old woman reported:
I was really excited to get it and everything. That’s 
what I wanted, was the [XR-NTX], but every time I 
make a plan to go into detox, right there I am ready 
and everything and then I can’t do it and back out. 
They come and pick me up and I’m in the car and…I 
have really, really bad anxiety. So it’s tense… It’s just 
the fear of everything. [Case ID 11]
A middle-aged respondent experiencing homelessness 
expressed that his inability to stop all opioids for more 
than a day had to do with being homeless and lacking a 
structured environment. He reported attempting to with-
draw on his own to prepare for induction: “I tried to detox 
but it wouldn’t happen for me.” [Case ID 16]. He was una-
ware of any medically supervised withdrawal centers in 
the area.
Some participants believed that transitioning directly 
from heroin or fentanyl was extremely difficult or impos-
sible. A 40-year-old man explained that he attempted 
going through withdrawal for the XR-NTX injection 
“three or four times” at home. He contemplated:
I know people take the shot but how do they get 
clean by taking it, you know what I mean? I think 
you all should have a way for them to methadone 
down, then detox off methadone, then probably take 
the shot. But that straight coming from heroin to the 
shot, that’s the hard stuff. Cold turkey. That’s why 
some people still out there now. They tried it, it don’t 
work. [Case ID 06]
He had been injecting heroin for 22 years and reported 
“buying methadone off the street” to taper off of heroin 
in preparation for his XR-NTX induction, but ended up 
enrolling in a methadone program instead:
[The study staff said] All right but you got to be 
totally clean, you can’t take any methadone or have 
none of that stuff in your system, nothing. It’s got to 
be like cold. And especially injecting, my withdraw-
als are more extreme than I think the ones who 
snorted. So I tried it. I tried it about two or three 
times but you can’t take nothing with opioids in it. 
Nothing to calm down your pain. It wasn’t working 
at all. Wasn’t working at all. So I just started metha-
done. So it’s been hard but now I’m on the metha-
done program and I ain’t used in about a month and 
a half so it’s been good. [Case ID 06]
A female respondent reported she “had once tried to 
commit suicide because I wanted to stop using so bad.” 
[Case ID 17] After 7 days of medically supervised with-
drawal, however, a naloxone challenge precipitated 
withdrawal.
I want the cravings to go away and that’s what the 
[XR-NTX] shot should do. I went through detox 
for seven days when I was doing the study, trying 
to get on the … shot but fentanyl was in my sys-
tem before I went in the detox and even after seven 
days, after finishing the detox, fentantyl was still 
in my system so I wasn’t able to get the shot. They 
gave me the [naloxone] to try to take it out of there 
but it instantly made me sick and I didn’t want to 
do another dose of [naloxone] because it made me so 
sick and then I went out and got me a bag of heroin 
that day. It made me go through withdrawals really 
bad, really quick. I was ready to leave instantly after 
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that. [Case ID 17]
As a result, she began a methadone program and, at the 
time of the interview, was still using some heroin to help 
with cravings. Her ultimate goal was to complete with-
drawal from opioids so that she can begin treatment with 
XR-NTX:
I have an appointment with my counselor next 
Wednesday to talk about me starting to decrease 
from the methadone so that I can get down so they 
can switch me to the [buprenorphine] again and 
then she can switch me to the [XR-NTX] shot. [Case 
ID 17]
Ambivalence about or reluctance to stop opioids
Ambivalence about stopping opioid use was common 
among participants and some identified the positive 
effects of opioid use that they would lose on XR-NTX. 
The potential negative effects of XR-NTX were also of 
concern. Participants feared, for example, that either they 
would have pain and be unable to manage it without opi-
oids, or they felt that opioids helped them cope with dif-
ficult life experiences. Others were simply not ready to 
stop. Two participants summarized their feelings:
I don’t want to stop yet and get this twenty day 
blocker. It’s definitely great for somebody who really 
wants to stop and doesn’t have reservations. [Case 
ID 10]
I’m not ready to get off heroin. I’m being honest. 
[Case ID 09]
A respondent felt that opioids helped him maintain 
employment by keeping him “well”. He was providing 
financial support to his brother and therefore prioritized 
his work over treatment:
Like when I am working, I just keep myself well….Some 
of my family tells me you know, it’s better that you just go 
into treatment for a while, get yourself together and then 
things will probably fall into place and get better. Which 
is true but by me just losing my mom a few months ago 
mentally I tell myself I need to just work so I can help my 
brother. [Case ID 03] One respondent discussed the com-
plexities of avoiding withdrawal and how that related to 
his feelings about treatment with XR-NTX:
For me, because me being used to getting high for so 
long over twenty-seven years, it’s going to be hard… 
I think I need to be on some medication that would 
get me close to that standard than to just do cold 
turkey. That’s still cold turkey to me—when you don’t 
get high period, when you are used to getting high. So 
it’s still a problem and I don’t want it to be a prob-
lem. Mentally.” [Case ID 15]
Similarly, a 55 year old man talked about continu-
ing to use heroin: “Cause I been doing it a long time 
I probably would have had to do some more even if 
I did take the shot.” [Case ID 16] When asked if he 
would prefer to continue to use heroin, he divulged, 
“For the moment, I am still using but I am really 
thinking about trying to get off….I thought I felt 
ready but I guess I am not, yet. [Case ID 16].
A 30-year-old respondent who did manual labor for a 
living described how the positive effects of using heroin, 
such as pain relief, outweighed the negative experiences 
like withdrawal and other possible consequences.
No, [I am not ready to stop]. … I don’t know, it’s 
weird, I want to but I don’t. When I stop, like I have 
physical problems and when I’m high I don’t have 
no aches, no pains, just when I’m like not actually 
high, just living that lifestyle, I don’t have any pain 
unless I just wake up in the morning and I am just 
feeling a little sick. That’s the only thing but when I 
get clean I have aches and pains and that’s-- it sucks. 
… I don’t know, I just don’t know, I got to see. I have 
been dodging bullets I’d say but you know, I just need 
to bite the bullet and go see doctors and psychiatrists 
you know, but…[Case ID 10]
Concerns about XR‑NTX effects
Some patients expressed negative perceptions about 
XR-NTX including fear of experiencing opioid with-
drawal, concerns about unmanaged pain, and the fact 
that it is not an opioid agonist. In addition, participants 
had previously received negative or potentially confus-
ing information about the extended-release formulation 
and were concerned that they would still have cravings, 
try to use higher amounts of opioids and increase the 
risk of overdose, or potentially increase use of stimulants 
when they were unable to use opioids. When asked about 
his perception of XR-NTX, a 36 year old Hispanic male 
reported:
Maybe it has to do with that it was females that 
were giving the [negative] feedback, just the females 
acted that way so, anyway, the females that told me 
about it, one of them told me that she was still sick 
after taking a shot of [XR-NTX]. The other one told 
me she turned into a crack addict-- a crack monster. 
[Case ID 10]
When asked what she had heard about XR-NTX, a 
female respondent reported that she had heard it was 
“a good thing but don’t you never do the dope because 
it’s going to kill you. Be ready you know in your heart you 
won’t do it no more”. [Case ID 01].
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Preferences for other medications
Though less commonly cited, a few participants assigned 
to XR-NTX preferred opioid agonist therapy with 
buprenorphine or methadone, particularly when they had 
prior beneficial experiences with either medication. In 
some cases, participants were exposed to buprenorphine 
or methadone during medically supervised withdrawal 
admissions and opted to remain on those medications 
even though they had been randomized to XR-NTX.
A male participant reported that after study staff found 
him an inpatient medically supervised withdrawal center, 
he was still testing positive for opioids. He was subse-
quently moved to a hospital, where he was provided 
buprenorphine.
So, the next step from the detox was the inpatient 
treatment at [name] … and I was there for four 
months … Did good while I was there. I stayed clean. 
I was introduced to the [buprenorphine] and it was 
working for me. I’m still using it. It’s still working for 
me. [Case ID 12]
In collaboration with his HIV provider, he decided it 
was best for him to remain on buprenorphine rather than 
initiate XR-NTX. Another individual reported a similar 
scenario; after being introduced to buprenorphine during 
his medically supervised withdrawal, he mulled over the 
decision about whether to switch to XR-NTX:
Well, when I heard, you know, at first I was going to 
switch over and then something just said, no, no, no. 
Stay with what you are doing because it’s working. 
So, I stayed on the [buprenorphine]. I was satisfied. 
[Case ID 13]
Discussion
The current study suggests that individuals who com-
pleted XR-NTX induction reported (1) readiness for 
change, (2) a supportive environment during withdrawal 
including comfort medications, and (3) caring interac-
tions with staff. Four contrasting themes emerged among 
participants (n = 17) who did not complete induction: 
(1) concern and anxiety about withdrawal including past 
negative experiences, (2) ambivalence about or reluctance 
to stop opioids, (3) concerns about XR-NTX effects, 
and (4) preferences for other medications. Of note, par-
ticipants who experienced inpatient medically managed 
withdrawal seemed to have an advantage over those who 
did not have access. Inpatient treatment served the pur-
pose of avoiding hazards associated with withdrawal and 
return to use; in this environment, supportive medica-
tions can make the early hours and days of withdrawal as 
comfortable as possible while removing the patient from 
their use environment. This is consistent with other stud-
ies showing that linking patients from inpatient managed 
withdrawal programs to long‐term long term MOUD 
treatment reduces illicit opioid use and increases days 
of treatment [33, 34]. To our knowledge, this is the first 
qualitative report of patients experiences with success-
ful, and unsuccessful XR-NTX induction and advances 
understanding of how to better support patients in initia-
tion of XR-NTX. The paper’s contribution to the litera-
ture is that it documents study participants’ experiences 
who tried but were unable to withdraw from opioids and 
did not receive an injection of extended-release naltrex-
one. Patients who completed induction also reported 
difficulty withdrawing but had sufficient social and envi-
ronmental support to overcome withdrawal symptoms 
and receive the first injection of XR-NTX.
The theme of motivation, or “readiness to change”, also 
played an important role and is a well-known predictor 
of treatment engagement [35]. Clinician assessment of 
a patient’s motivation and use of techniques to advance 
progression along stages of readiness such as Motiva-
tional Interviewing may be helpful.
Patient preference also influenced participant enthu-
siasm for treatment initiation, with some participants 
indicating that their preference for opioid agonist treat-
ment dampened their enthusiasm for XR-NTX induc-
tion. Patient preference was similarly associated with 
treatment outcome in a large comparative effectiveness 
trial of XR-NTX versus buprenorphine [19]. National 
treatment guidelines endorse shared decision-making 
in choosing medications for OUD [36]. Development 
of patient-facing decision aids, as developed for other 
medical treatments, may enhance patient-centered, 
informed decision-making in choice of OUD treat-
ment [37]. Our results are also consistent with another 
recent investigation which found that it is more difficult 
to induct patients onto XR-NTX than buprenorphine, 
though requirements for a negative-buprenorphine 
urine sample before XR-NTX induction may have exac-
erbated the underlying withdrawal tolerance issues [19]. 
Additionally, in a previous study of CHOICES study 
staff, Hoffman et  al. [21] found that a specific medi-
cation-related barrier to induction was patient fear of 
opioid abstinence required prior to XR-NTX induction. 
Similar results have been found in other studies of indi-
viduals using stimulants and opioids [31]. Overcoming 
these barriers to XR-NTX induction may require addi-
tional counseling on how XR-NTX works, expectations 
for induction, aggressive advance treatment of opioid 
withdrawal symptoms (e.g., standing doses of clonidine, 
trazodone for sleep, hydroxyzine for anxiety, etc.), and 
respect for patient preferences for opioid agonist ver-
sus antagonist treatment. Study participants perceived 
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that withdrawal from fentanyl was more difficult than 
other opioids and a subsequent quantitative analysis 
confirmed that induction rates were substantially lower 
among individuals with fentanyl positive urine screens 
(adjusted hazard ratio = 0.09, 95% confidence interval 
0.03 to 0.24) [38]. This study points to the need for new 
clinical interventions to manage fentanyl withdrawal.
Some limitations of the study should be acknowl-
edged. It is important to note that this study was explor-
atory and assessed barriers and facilitators to XR-NTX 
induction among a convenience sample of individuals 
already enrolled in a treatment trial. It did not include 
all patients in the trial, and thus may not represent all 
views. Another limitation concerns the generalizabil-
ity of the findings. The relatively small sample of indi-
viduals enrolled in a trial and receiving compensation 
may not reflect the general population of those seeking 
treatment for opioid use disorder. Additionally, there 
was heterogeneity of sample demographics, interview 
method (in-person, telephone), and induction settings.
Conclusions
The results highlight areas that need to be addressed in 
order to improve uptake of XR-NTX. In the U.S., new 
policies and guidelines are increasingly proposed and 
adopted to address the opioid epidemic but more is 
needed to reach high-needs populations, such as those 
living with uncontrolled HIV disease [20]. Successful 
induction onto XR-NTX can be associated with a sup-
portive and safe setting for withdrawal management, 
use of ancillary medication to minimize opioid with-
drawal symptoms, and support from staff, family and 
friends. Shared decision making that prioritizes patient 
preferences helps patients better understand the effects 
of opioid agonist and opioid antagonist therapies may 
improve initiation of medications for opioid use disor-
der treatment.
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